- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-5076
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean? ; volume:15 ; number:1 ; day:22 ; month:12 ; year:2021 ; pages:45-48 ; date:2.2022
Magazine of European Medical Oncology ; 15, Heft 1 (22.12.2021), 45-48, 2.2022
- Urheber
-
Prochazka, Katharina T.
Uhl, Barbara
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12254-021-00778-2
- URN
-
urn:nbn:de:101:1-2022052107443720938857
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Prochazka, Katharina T.
- Uhl, Barbara
- SpringerLink (Online service)
Ähnliche Objekte (12)
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
Mechanismen erworbener Resistenz gegenüber den BCL2-Inhibitoren ABT-737 und ABT-199 (Venetoclax) in der chronischen lymphatischen Leukämie
XIII. - Remissions
XIII. - Remissions
XIV. Remissions
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion
Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway
Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax
Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression
Remissions- und Fristbewilligungsgesuche
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
Mechanismen erworbener Resistenz gegenüber den BCL2-Inhibitoren ABT-737 und ABT-199 (Venetoclax) in der chronischen lymphatischen Leukämie
XIII. - Remissions
XIII. - Remissions
XIV. Remissions
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion
Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway
Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax
Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression
Remissions- und Fristbewilligungsgesuche
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
Mechanismen erworbener Resistenz gegenüber den BCL2-Inhibitoren ABT-737 und ABT-199 (Venetoclax) in der chronischen lymphatischen Leukämie
XIII. - Remissions
XIII. - Remissions
XIV. Remissions
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion
Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway
Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax
Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression